Managing Ocular Toxicities Associated with Antibody-Drug Conjugates and Other Cancer Therapies — Part 2 — Video Interview

Faculty

TARGET AUDIENCE
This activity is intended for medical oncologists, hematologists, hematology-oncology fellows, oncology surgeons, radiation oncologists and other allied healthcare professionals involved in the treatment of cancer.

LEARNING OBJECTIVES

• Appreciate the pathophysiology of ocular toxicities associated with the administration of specific anticancer therapies for various solid tumors and hematologic cancers.
• Understand the frequency and severity of ocular toxicities observed in pivotal trials evaluating novel agents and strategies demonstrating efficacy in various tumor types, and educate patients about to begin therapy with these approaches regarding the potential development of these adverse events (AEs) and what to do if they are suspected.
• Recall strategies commonly employed to identify, manage and mitigate ocular toxicities in patients receiving anticancer treatment, and use this information to appropriately intervene when these side effects are suspected or diagnosed.
• Appraise the role of multidisciplinary specialists such as ophthalmologists and other eye-care professionals in the diagnosis and management of ocular toxicities, and effectively collaborate with these clinicians to offer best-practice care for patients at high risk for or with a suspected or confirmed diagnosis of these AEs.

ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT
Research To Practice designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
Successful completion of these CME activities, which includes participation in the evaluation components and post-tests, enables the participant to earn up to 1.25 (video) Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for each activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, these programs have been specifically designed for the following ABIM specialty: medical oncology and hematology.

PRIVACY POLICY
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

HOW TO USE THIS CME ACTIVITY
This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the post-test with a score of 80% or better and fill out the evaluation located at ResearchToPractice.com/InsideTheIssue2025/OcularToxicities/Part2/Video/CME.

CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Neel Pasricha, MD
Assistant Professor of Ophthalmology
University of California, San Francisco
San Francisco, California

Advisory Committees: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Sanofi; Consulting Agreements: Amgen Inc, Curie.Bio, Vanda Pharmaceuticals Inc.

EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeOne, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Clovis Oncology, Coherus BioSciences, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Helsinn Therapeutics (US) Inc, Hologic Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

These educational activities contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

These activities are supported by educational grants from AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, and GSK.

Release date: September 2025
Expiration date: September 2026

After completing the post-test, learners may download and review the answers here in order to identify further areas of study.

Bardia A et al. Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor–positive human epidermal growth factor receptor 2–negative breast cancer: Primary results from TROPION-Breast01. J Clin Oncol 2025;43(3):285-96. Abstract

Beksac M et al. Baseline ocular conditions and risk of ocular events in patients (pts) with relapsed/refractory multiple myeloma (RRMM) from the DREAMM-7 and DREAMM-8 trials of belantamab mafodotin (belamaf). ASCO 2025;Abstract 7544.

Canestraro J et al. Refractive shifts and changes in corneal curvature associated with antibody-drug conjugates. Cornea 2022;41(6):792-801. Abstract

Fortes BH et al. Ophthalmic adverse effects of immune checkpoint inhibitors: The Mayo Clinic experience. Br J Ophthalmol 2021;105(9):1263-71. Abstract

Francis JH et al. Mitogen-activated pathway kinase inhibitor-associated retinopathy: Do features differ with upstream versus downstream inhibition? Ocul Oncol Pathol 2023;9(1-2):25-31. Abstract

Hattin R et al. Incidence of ocular toxicities in patients with relapsed/refractory multiple myeloma treated with belantamab mafodotin: A systematic review and meta-analysis of phase 3 randomized controlled trials. ASCO 2025;Abstract 12040.

Heist RS et al. Clinical management, monitoring, and prophylaxis of adverse events of special interest associated with datopotamab deruxtecan. Cancer Treat Rev 2024;125:102720. Abstract

Hultcrantz M et al. Belantamab mafodotin monotherapy for relapsed or refractory multiple myeloma: A real-world observational study in the United States. Haematologica 2025;110(3):753-7. Abstract

Hungria V et al. Practical guidance on the clinical management of ocular adverse events associated with belantamab mafodotin for patients with relapsed/refractory multiple myeloma: Latin American expert panel recommendations. Oncol Ther 2025. Abstract

Jhaveri K et al. Datopotamab deruxtecan (Dato-DXd) vs chemotherapy (CT) in pretreated, inoperable/metastatic HR+/HER2– breast cancer (BC): Additional safety analysis from TROPION-Breast01. ESMO Breast 2024;Abstract LBA2.

Kim SK et al. Mitigation and management strategies for ocular events associated with tisotumab vedotin. Gynecol Oncol 2022;165(2):385-92. Abstract

Kleinman D et al. PLL-g-PEG polymer inhibits antibody-drug conjugate uptake into human corneal epithelial cells in vitro. J Ocul Pharmacol Ther 2024;40(7):419-27. Abstract

Landzberg R et al. Portable eye examinations in the oncology clinic: An innovative pilot for clinical trial screening. CERSI Summit 2025.

Lee BA et al. Clinical and histological characterization of toxic keratopathy from depatuxizumab mafodotin (ABT-414), an antibody-drug conjugate. Cornea 2021;40(9):1197-200. Abstract

Lee V et al. Characterization of belantamab mafodotin–induced corneal changes in patients with multiple myeloma. JAMA Ophthalmol 2025;143(6):507-14. Abstract

Lent-Schochet D et al. Ocular surface disease related to tisotumab vedotin-tftv. Gynecol Oncol Rep 2025;57:101676. Abstract

Lindgren ES et al. Incidence and mitigation of corneal pseudomicrocysts induced by antibody–drug conjugates (ADCs). Curr Ophthalmol Rep 2024;12(2):13-22. Abstract

Loberg LI et al. Characterization and potential mitigation of corneal effects in nonclinical toxicology studies in animals administered depatuxizumab mafodotin. J Ocul Pharmacol Ther 2022;38(7):471-80. Abstract

Lu R et al. Management of ocular toxicity in patients receiving belantamab mafodotin. J Adv Pract Oncol 2023;14(4):300-6. Abstract

Mateos M-V et al. Results from the randomized phase III DREAMM-7 study of belantamab mafodotin (belamaf) + bortezomib, and dexamethasone (BVd) vs daratumumab, bortezomib, and dexamethasone (DVd) in relapsed/refractory multiple myeloma (RRMM). ASCO 2024;Abstract 439572.

Munawar U et al. Soluble B-cell maturation antigen in lacrimal fluid as a potential biomarker and mediator of keratopathy in multiple myeloma. Haematologica 2024;109(11):3670-80. Abstract

Pistilli B et al. Datopotamab deruxtecan (Dato-DXd) vs chemotherapy (CT) in previously-treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2–) breast cancer (BC): Final overall survival (OS) from the phase III TROPION-Breast01 trial. ESMO Virtual Plenary;Abstract VP1-2025.

Trudel S et al. Results from the randomized phase 3 DREAMM-8 study of belantamab mafodotin plus pomalidomide and dexamethasone (BPd) vs pomalidomide plus bortezomib and dexamethasone (PVd) in relapsed/refractory multiple myeloma (RRMM). ASCO 2024;Abstract LBA105.

Tu Y-P et al. Exposure-response relationships of mirvetuximab soravtansine in patients with folate receptor-α-positive ovarian cancer: Justification of therapeutic dose regimen. Br J Clin Pharmacol 2025;91(1):220-31. Abstract

Usmani SZ et al. Phase I study of belantamab mafodotin in combination with standard of care in transplant-ineligible newly diagnosed multiple myeloma: Dreamm-9 updated interim analysis. ASH 2024;Abstract 497.

Warbington A et al. Nonclinical ocular toxicity of a maytansinoid payload-antibody drug conjugate: Ocular tissue distribution, lesion pathogenesis, and mitigation. AACR 2024;Abstract 2591.

Zhao H et al. Modulation of macropinocytosis-mediated internalization decreases ocular toxicity of antibody-drug conjugates. Cancer Res 2018;78(8):2115-26. Abstract